(Q39546197)

12 September 2017

title

Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2'-Deoxycytidine (English)

1 reference

12 September 2017

10

Angus Dalgleish

1 reference

12 September 2017

Mengyong Yan

1

1 reference

12 September 2017

Nourredine Himoudi

2

1 reference

12 September 2017

B Piku Basu

3

1 reference

12 September 2017

Rebecca Wallace

4

1 reference

12 September 2017

Edmund Poon

5

1 reference

12 September 2017

Stuart Adams

6

1 reference

12 September 2017

Fyeza Hasan

7

1 reference

12 September 2017

Shao-An Xue

8

1 reference

12 September 2017

Natalie Wilson

9

1 reference

12 September 2017

Owen Williams

11

1 reference

12 September 2017

John Anderson

12

1 reference

12 September 2017

publication date

7 May 2011

1 reference

Cancer Immunology, Immunotherapy

12 September 2017

published in

1 reference

12 September 2017

volume

60

1 reference

12 September 2017

issue

9

1 reference

12 September 2017

page(s)

1243-1255

1 reference

Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

Gene expression profiling predicts clinical outcome of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

PRAME expression and clinical outcome of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

PRAME gene expression in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

Gene expression changes associated with progression and response in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

Induction of MAGE-3 expression in lung and esophageal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

Treatment of ovarian cancer cell lines with 5-aza-2'-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

Development of cellular immune responses against PAX5, a novel target for cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

The role of decitabine in the treatment of myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

Epigenetic therapy of leukemia: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

Review: recent clinical trials in epigenetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

DNA methylation and chromatin structure regulate T cell perforin gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

Treatment with demethylating agent, 5-aza-2'-deoxycytidine enhances therapeutic HPV DNA vaccine potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1024-4

10.1007/S00262-011-1024-4

21 January 2018

Identifiers

DOI

1 reference

12 September 2017

1 reference